- Currently Available in Canada -
TORONTO, Sept. 10, 2018 /CNW/ - Teva Canada Limited, a
subsidiary of Teva Pharmaceutical Industries Ltd., announces that
the complete line of PrTeva-Aripiprazole (2 mg, 5 mg,
10 mg, 15 mg, 20 mg and 30 mg tablets), a Health Canada
approved, bioequivalent generic version of PrAbilify®
(aripiprazole) is now available in Canada. This once-daily extended release
prescription medication is indicated for the treatment of
schizophrenia in adolescents 15-17 years of age and adults 18 years
of age or older.
"Each day, over 300,000i Canadians living with
schizophrenia, their families and caregivers, deal with profound
physical, emotional and financial tolls," said Christine Poulin, Senior Vice President and
General Manager, Teva Canada. "The
cost of their medication should not be part of the challenge. The
launch of PrTeva-Aripiprazole provides patients with an
affordable, bioequivalent alternative to PrAbilify® and
demonstrates our ongoing commitment to improving people's
lives."
Aripiprazole tablets (brand: PrAbilify®) had annual
sales of approximately $182 million
in Canada, based on IQVIA sales
data as of July 2018.
PrTeva-Aripiprazole is available immediately to
pharmacies across Canada. This launch broadens Teva Canada's portfolio of medicines that treat
mental health conditions to 28, including seven in the same
therapeutic class as PrTeva-Aripiprazole
(antipsychotic), all of which provide patients and payors with a
full spectrum of affordable treatment options.
About Schizophrenia
Schizophrenia affects approximately 1% of the population in
Canada or 1 in 100 persons. It is
a severe mental disorder, characterized by profound disruptions in
thinking, affecting language, perception, and the sense of self. It
often includes psychotic experiences, such as hearing voices or
delusions. It can impair functioning through the loss of an
acquired capability to earn a livelihood, or the disruption of
studies. Schizophrenia typically begins in late adolescence or
early adulthood. Antipsychotic medication forms the cornerstone of
treatment for schizophrenia.ii While there is no cure
for schizophrenia, medication can reduce symptoms and significantly
reduce relapses, and people affected by it can lead a productive
life, integrated into society.iii
Helping People Live Better Days
At Teva, we help to improve the health of 200 million people
every day by providing innovative treatments and access to the
world's largest medicine cabinet of generic and specialty
medicines. This gives us a unique perspective on health.
Understanding the many ways health impacts people's lives inspires
us to discover new possibilities to bring medicines and more,
enabling patients and caregivers to live better days.
About Teva Canada Limited
Teva Canada Limited, headquartered in Toronto, has provided affordable healthcare
solutions for over 50 years, with sales of more than $1 billion in 2017 and over 249,000 prescriptions
filled with our products every dayiv. Originally
Novopharm Limited, Teva Canada Limited specializes in the
development, production and marketing of high-quality generic
prescription pharmaceuticals and through our branded division, Teva
Canada Innovation, focuses on a diverse line of innovative products
in a variety of therapeutic areas. Teva
Canada employs more than 1,000 professionals, markets more
than 400 productsv in 1,700 SKUs in Canada and is a subsidiary of Teva
Pharmaceutical Industries Ltd., the world's largest generic drug
maker. For more information, visit: www.tevacanada.com or
www.tevamakesmedicines.ca.
About Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA)
is a global leader in generic medicines, with innovative treatments
in select areas, including CNS, pain and respiratory. We deliver
high-quality generic products and medicines in nearly every
therapeutic area to address unmet patient needs. We have an
established presence in generics, specialty, OTC and API, building
on more than a century-old legacy, with a fully integrated R&D
function, strong operational base and global infrastructure and
scale. We strive to act in a socially and environmentally
responsible way. Headquartered in Israel, with production and
research facilities around the globe, we employ 45,000
professionals, committed to improving the lives of millions of
patients. Learn more at www.tevapharm.com.
__________________________________
|
i
|
Sources: Government
of Canada, Public Health Agency of Canada Reports and Publications
Archived: A Report on Mental Illnesses in Canada – Schizophrenia
https://www.canada.ca/en/public-health/services/reports-publications/report-on-mental-illnesses-canada/schizophrenia.html
| Statistics Canada, CANSIM, Table 051-0001 - Population as of July
1, 2017 | Population Estimates and Projections | Population by
sex and age group
http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/demo10a-eng.htm
– Accessed September 2018
|
ii
|
Source: Government of
Canada, Public Health Agency of Canada Reports and Publications
Archived: A Report on Mental Illnesses in Canada – Schizophrenia
https://www.canada.ca/en/public-health/services/reports-publications/report-on-mental-illnesses-canada/schizophrenia.html
– Accessed September 2018
|
iii
|
Sources: American
Psychiatric Association - What Is Schizophrenia?
https://www.psychiatry.org/patients-families/schizophrenia/what-is-schizophrenia
| Canadian Mental Health Association - Mental Health -
Understanding Mental Illness - Schizophrenia
https://cmha.ca/mental-health/understanding-mental-illness/schizophrenia |
World Health Organization - What is schizophrenia?
http://www.who.int/mental_health/management/schizophrenia/en/ –
Accessed September 2018
|
iv
|
Source: IQVIA CDH
& Compuscript MAT January 2018
|
v
|
Source: IQVIA CDH
& Compuscript MAT January
2018
|
SOURCE Teva Canada Limited